E2F3 and prostate carcinoma: Still, one scenario based on Wang et al.’s study on prostate cancer suggests that downregulation of hsa-miR-194-5p is linked to overexpression of the oncogene E2F transcription factor 3 (E2F3), which can improve cancer progression [31, 84].